Company logo
Sector: Healthcare
Industry: Drug Manufacturers—general

Johnson & Johnson

Ticker - JNJ
Country: US
Exchange: NYSE

Monitor Performance using this Dynamic, Always Current, Periodic Table of Investments

Data:

Time:

Alignment:

About Johnson & Johnson

  • Company Overview
    • Johnson & Johnson (JNJ) is a diversified multinational corporation that operates in the healthcare sector, focusing on pharmaceuticals, medical devices, and consumer health products.
    • Founded in 1886, JNJ is recognized for its extensive brand portfolio which includes well-known names across its various business segments.
  • Johnson & Johnson (JNJ) is a diversified multinational corporation that operates in the healthcare sector, focusing on pharmaceuticals, medical devices, and consumer health products.
  • Founded in 1886, JNJ is recognized for its extensive brand portfolio which includes well-known names across its various business segments.
  • Business Segments
    • Pharmaceuticals: This segment is JNJ’s largest revenue generator, featuring products in areas such as immunology, oncology, neuroscience, and infectious diseases. Key brands include Remicade, Stelara, and Imbruvica.
    • Medical Devices: JNJ has a diverse range of medical device offerings that cater to orthopedics, surgery, cardiovascular, and vision care. Brands include DePuy Synthes and Ethicon.
    • Consumer Health: This division produces over-the-counter products and wellness products, with brands like Tylenol, Band-Aid, and Neutrogena. This segment is highly recognized by consumers but is less profitable compared to others.
  • Pharmaceuticals: This segment is JNJ’s largest revenue generator, featuring products in areas such as immunology, oncology, neuroscience, and infectious diseases. Key brands include Remicade, Stelara, and Imbruvica.
  • Medical Devices: JNJ has a diverse range of medical device offerings that cater to orthopedics, surgery, cardiovascular, and vision care. Brands include DePuy Synthes and Ethicon.
  • Consumer Health: This division produces over-the-counter products and wellness products, with brands like Tylenol, Band-Aid, and Neutrogena. This segment is highly recognized by consumers but is less profitable compared to others.
  • Financials
    • JNJ has historically demonstrated strong revenue growth and profitability, buoyed by its diversified portfolio which helps mitigate risks associated with dependence on a single product or market.
    • The company features a stable cash flow generation ability, which supports dividends and ongoing investments in research & development.
    • JNJ’s commitment to returning capital to shareholders has resulted in a long-standing track record of dividend payments, making it a staple in many income-focused portfolios.
  • JNJ has historically demonstrated strong revenue growth and profitability, buoyed by its diversified portfolio which helps mitigate risks associated with dependence on a single product or market.
  • The company features a stable cash flow generation ability, which supports dividends and ongoing investments in research & development.
  • JNJ’s commitment to returning capital to shareholders has resulted in a long-standing track record of dividend payments, making it a staple in many income-focused portfolios.
  • Market Position
    • Johnson & Johnson is one of the largest players in the healthcare sector, with a strong competitive advantage derived from its extensive research capabilities, large scale, and diverse product lines.
    • The company benefits from well-established distribution networks and significant market share in both pharmaceuticals and consumer health products.
  • Johnson & Johnson is one of the largest players in the healthcare sector, with a strong competitive advantage derived from its extensive research capabilities, large scale, and diverse product lines.
  • The company benefits from well-established distribution networks and significant market share in both pharmaceuticals and consumer health products.
  • Competitive Dynamics
    • JNJ faces competition from both generic and branded pharmaceutical companies, which poses a persistent challenge to maintaining pricing power and market share in the pharmaceutical space.
    • In the medical devices sector, innovation is a key driver of market positioning, compelling JNJ to continually invest in R&D to remain competitive.
  • JNJ faces competition from both generic and branded pharmaceutical companies, which poses a persistent challenge to maintaining pricing power and market share in the pharmaceutical space.
  • In the medical devices sector, innovation is a key driver of market positioning, compelling JNJ to continually invest in R&D to remain competitive.
  • Risks and Challenges
    • Regulatory risks are significant within the healthcare industry, with product approvals and compliance being critical to operational success.
    • The reliance on certain blockbuster drugs for revenue can pose risks, especially as patents expire and generics enter the market.
    • Litigation risks related to product liability claims can also impact JNJ, particularly in its consumer health segment.
  • Regulatory risks are significant within the healthcare industry, with product approvals and compliance being critical to operational success.
  • The reliance on certain blockbuster drugs for revenue can pose risks, especially as patents expire and generics enter the market.
  • Litigation risks related to product liability claims can also impact JNJ, particularly in its consumer health segment.
    • SWOT ANALYSIS

    SWOT Analysis is a strategic planning tool used to identify and understand the key factors that can impact a business or project. What are the key factors for gaining a competitive market share advantage? Also, what potential threats should we be wary of during our Process?

    STRENGTHS

    • JNJ has a diversified product portfolio across pharmaceuticals, medical devices, and consumer health, reducing dependency on any single segment.
    • The company boasts strong brand recognition and trust in its consumer health products while maintaining a prominent position in the pharmaceutical and medical device sectors.
    • JNJ consistently generates robust cash flow, enabling ongoing investment in R&D and shareholder returns through dividends and buybacks.
    • Strong global presence with extensive distribution networks enhances market access and competitive edge.

    WEAKNESSES

    • JNJ faces ongoing litigation risks, including safety and product liability lawsuits, that can impact financial performance and reputational standing.
    • Dependence on a limited number of blockbuster drugs for a significant portion of revenue poses vulnerability to patent expirations and competitive entry.
    • The company's large size can lead to bureaucratic inefficiencies and slow response times to market changes compared to more agile competitors.

    OPPORTUNITIES

    • Expansion into emerging markets presents significant revenue growth opportunities due to increasing healthcare needs and consumer spending.
    • Advancements in biotechnology and personalized medicine offer avenues for developing innovative therapies and products to meet evolving patient demands.
    • Strategic acquisitions could enhance JNJ's capabilities and market reach in high-growth areas within the healthcare sector.

    THREATS

    • Intense competition from generic drugs and biosimilars could erode market share and pricing power for key products.
    • Regulatory changes and healthcare reforms can create uncertainty and potential compliance costs that impact profitability.
    • Shifts in consumer preferences towards alternative therapies and wellness solutions may challenge traditional product sales.

    Please enjoy this free portfolio visualization and monitoring tool. Click Install from the address bar for easy and fast future access.

    Paid accounts can visualize any portfolio or watchlist in this performance visualization… plus a million other cool things — including daily data, sharing custom tables for the assets you care about, industry-leading portfolio backtesting, and full portfolio strategy analytics. Both individual and professional versions are supported.

    Performance Disclosure

    This portfolio is hypothetical.


    This is a historical simulation of the portfolio performance an investor would have obtained had you invested in the same selections at the beginning of the simulation. This report provides information on how the portfolio holdings would have changed and would have performed for a certain period. We have strived to reduce or eliminate potential biases in the process to provide the most accurate assessment of the performance prospects of the strategy. However, it may not be possible for any historical simulation to completely ensure it is free of all biases.


    Please see
    Gold Standard for Portfolio Backtesting and
    Seven Deadly Sins of Portfolio Backtesting
    for a more complete understanding of risks and biases when backtesting portfolio strategies.


    Backtested strategies also run the risk of cherry picking. Cherry Picking is when the author of the backtest has created many variations and is presenting one of the variations that is more favorable. This research was not produced in whole or in part by cherry picking.


    This simulation is based on an account with tax exempt or tax deferred growth. Taxable accounts will have to pay the appropriate taxes for dividends, interest, and capital gains, which will decrease the performance depicted.


    This simulation is not based on actual trading accounts or account composites which may or may not exist for this strategy and may be materially different including worse than the performance illustrated above. Past performance is not necessarily indicative of future performance. Performance results including risk and diversification measures are not guaranteed to persist in the future.


    This historical performance simulation has been adjusted to reflect estimated management fees.


    The suitability of this portfolio strategy requires that you have thoughtfully and accurately completed your investor objectives from your accounts’ Investment Policy Statement. Login


    Diversification strategies alone cannot assure a successful investment outcome. Strategies offering greater diversification also fail to guarantee any reduction in loss of capital.


    Your ability to follow this investment strategy is a risk. Investors often dispose of successful strategies at inopportune times thus turning potentially profitable strategies into losses.


    Portfolio data is taken from sources believed to be accurate, however, there is no warranty or guarantee as to the accuracy or completeness of data and statistical calculations thereupon. Portfolio ThinkTank does not furnish investment advice without an investment advisory agreement.


    The period of time selected for analysis may have a significant bearing on the relative attractiveness of the strategy and the strategy versus another portfolio or benchmark. The author of the strategy controls the default period of time used to analyze performance and from there, users may select any desired period of time from the menu. In general, longer periods, greater diversification and lower concentrations of holdings result in more credible, more persistent performance evaluations.


    If this strategy includes predictions created by our deep learning neural net, there are additional risks that portfolio strategies and their backtested performance may have risks of having the data be overfit and consequently perform better in the backtest than it may in real account performance. We manage these risks regularly and in many ways. However, due to the attention mechanisms in a deep learning neural network, it may not be possible to eliminate these risks. To learn if your portfolio strategy is built using predictions from a neural network or to better understand our mitigation policies, we invite you to start a conversation: hello@gravityinvestments.com